keyword
MENU ▼
Read by QxMD icon Read
search

Vedolizumab

keyword
https://www.readbyqxmd.com/read/28620302/adoption-of-biosimilar-infliximab-for-rheumatoid-arthritis-ankylosing-spondylitis-and-inflammatory-bowel-diseases-in-the-eu5-a-budget-impact-analysis-using-a-delphi-panel
#1
Tim A Kanters, Jelena Stevanovic, Isabelle Huys, Arnold G Vulto, Steven Simoens
Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn's disease and ulcerative colitis) may reduce treatment costs associated with biologics. This study aimed to investigate the budget impact of adopting biosimilar infliximab in five European countries, considering that the budget impact includes the adoption of biosimilar infliximab and the availability of biologic alternatives such as vedolizumab, biosimilar etanercept, biosimilar rituximab, and other relevant factors...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28605483/vedolizumab-in-pediatric-inflammatory-bowel-disease-a-retrospective-multi-center-experience-from-the-paediatric-ibd-porto-group-of-espghan
#2
Oren Ledder, Amit Assa, Arie Levine, Johanna C Escher, Lissy de Ridder, Frank Ruemmele, Neil Shah, Ron Shaoul, Victorien M Wolters, Astor Rodrigues, Holm H Uhlig, Carsten Posovsky, Kaija-Leena Kolho, Christian Jakobsen, Shlomi Cohen, Dror S Shouval, Tim de Meij, Javier Martin-de-Carpi, Lisa Richmond, Jiri Bronsky, Mira Friedman, Dan Turner
Background: Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with Inflammatory Bowel Disease (IBD), but the data in pediatrics are limited. We describe the short-term effectiveness and safety of vedolizumab in a European multi-center pediatric IBD cohort. Method: Retrospective review of children (2-18 years) treated with vedolizumab from 19 centers affiliated with the Paediatric IBD Porto group of ESPGHAN. Primary outcome was week 14 corticosteroid-free remission (CFR)...
June 9, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28593685/one-year-effectiveness-and-safety-of-vedolizumab-therapy-for-inflammatory-bowel-disease-a-prospective-multicentre-cohort-study
#3
A Amiot, M Serrero, L Peyrin-Biroulet, J Filippi, B Pariente, X Roblin, A Buisson, C Stefanescu, C Trang-Poisson, R Altwegg, P Marteau, T Vaysse, A Bourrier, S Nancey, D Laharie, M Allez, G Savoye, J Moreau, L Vuitton, S Viennot, A Aubourg, A-L Pelletier, G Bouguen, V Abitbol, C Gagniere, Y Bouhnik
BACKGROUND: We recently showed that vedolizumab is effective in patients with Crohn's disease (CD) and ulcerative colitis (UC) with prior anti-TNF failure in a multicentre compassionate early-access programme before marketing authorisation was granted to vedolizumab. AIMS: To assess effectiveness and safety of vedolizumab at week 54 in patients UC and CD. METHODS: Between June and December 2014, 173 patients with Crohn's disease (CD) and 121 with ulcerative colitis (UC) were treated with vedolizumab induction therapy...
June 8, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28575290/bringing-the-mucosa-to-heal-with-vedolizumab-in-patients-with-inflammatory-bowel-disease
#4
Satimai Aniwan, Edward V Loftus
No abstract text is available yet for this article.
May 27, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28537467/dose-escalation-of-biologics-in-crohn-s-disease-critical-review-of-observational-studies
#5
Thomas R Einarson, Basil G Bereza, Xin Ying Lee, Filippo Lelli
BACKGROUND: Biologics used to treat Crohn's disease (CD) may lose their effect over time, requiring dose escalation. Little information is available on this topic. AIM: To summarize rates of dose escalation, duration, de-escalation in observational studies of CD in adults treated with adalimumab, infliximab, and vedolizumab in Europe. METHODS: Two independent investigators searched Medline and Embase for observational studies published in 1998-2015 and proceedings from four major scientific meetings...
June 11, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28531313/mucosal-healing-in-ulcerative-colitis-patients-treated-with-vedolizumab-patient-dose-or-duration-dependant
#6
Rui Gaspar, Rodrigo Liberal, Guilherme Macedo
No abstract text is available yet for this article.
May 22, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28523450/a-review-of-the-clinical-pharmacokinetics-pharmacodynamics-and-immunogenicity-of-vedolizumab
#7
REVIEW
Maria Rosario, Nathanael L Dirks, Catherine Milch, Asit Parikh, Michael Bargfrede, Tim Wyant, Eric Fedyk, Irving Fox
Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD), vedolizumab is administered as a 300 mg intravenous infusion. Vedolizumab undergoes a rapid, saturable, non-linear, target-mediated elimination process at low concentrations and a slower, linear, non-specific elimination process at higher concentrations...
May 18, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28509816/variations-in-health-insurance-policies-regarding-biologic-therapy-use-in-inflammatory-bowel-disease
#8
Abhijeet Yadav, Joshua Foromera, Ilana Feuerstein, Kenneth R Falchuk, Joseph D Feuerstein
BACKGROUND: The American Gastroenterological Association (AGA) has developed guidelines for the management of ulcerative colitis and Crohn's disease (CD) recommending anti-TNF therapy in moderate-severe disease. However, which drug is used is often dictated by insurance company policies. We sought to determine the insurance policy requirements prior to approval of biologic therapies. METHODS: Using the National Association of Insurance Commissioners report of the top 125 insurance companies by market share in 2014, we reviewed the first 50 that had online policies regarding anti-TNF and vedolizumab available...
June 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28509767/variations-in-health-insurance-policies-regarding-biologic-therapy-use-in-inflammatory-bowel-disease
#9
Abhijeet Yadav, Joshua Foromera, Ilana Feuerstein, Kenneth R Falchuk, Joseph D Feuerstein
BACKGROUND: The American Gastroenterological Association (AGA) has developed guidelines for the management of ulcerative colitis and Crohn's disease (CD) recommending anti-TNF therapy in moderate-severe disease. However, which drug is used is often dictated by insurance company policies. We sought to determine the insurance policy requirements prior to approval of biologic therapies. METHODS: Using the National Association of Insurance Commissioners report of the top 125 insurance companies by market share in 2014, we reviewed the first 50 that had online policies regarding anti-TNF and vedolizumab available...
May 15, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28503977/emerging-treatments-for-ulcerative-colitis-a-systematic-review
#10
Damianos G Kokkinidis, Eftychia E Bosdelekidou, Sotiria Maria Iliopoulou, Alexandros G Tassos, Pavlos T Texakalidis, Konstantinos P Economopoulos, Antonis A Kousoulis
OBJECTIVES: Various investigational medicinal products have been developed for ulcerative colitis (UC). Our aim was to systematically evaluate novel pharmacological therapeutic agents for the treatment of UC. MATERIAL AND METHODS: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations were followed. A search of the medical literature was conducted in the MEDLINE database for original research papers published between 01 January 2010 and 31 October 2014...
May 14, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28501828/vedolizumab-a-novel-medical-intervention-in-the-treatment-of-primary-sclerosing-cholangitis
#11
Donevan Westerveld, Joseph Grajo, Lars Beattie, Sarah Glover
No abstract text is available yet for this article.
May 13, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28494241/gut-microbiome-function-predicts-response-to-anti-integrin-biologic-therapy-in-inflammatory-bowel-diseases
#12
Ashwin N Ananthakrishnan, Chengwei Luo, Vijay Yajnik, Hamed Khalili, John J Garber, Betsy W Stevens, Thomas Cleland, Ramnik J Xavier
The gut microbiome plays a central role in inflammatory bowel diseases (IBDs) pathogenesis and propagation. To determine whether the gut microbiome may predict responses to IBD therapy, we conducted a prospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients initiating anti-integrin therapy (vedolizumab). Disease activity and stool metagenomes at baseline, and weeks 14, 30, and 54 after therapy initiation were assessed. Community α-diversity was significantly higher, and Roseburia inulinivorans and a Burkholderiales species were more abundant at baseline among CD patients achieving week 14 remission...
May 10, 2017: Cell Host & Microbe
https://www.readbyqxmd.com/read/28469372/a-rare-case-of-crohn-s-ileitis-in-a-patient-with-constitutional-mismatch-repair-deficiency
#13
Pavlos Kaimakliotis, Francis Giardiello, Ogechukwu Eze, Brindusa Truta
Constitutional mismatch repair deficiency (CMMRD), a variant of Lynch syndrome, is a rare disease characterized by café-au-lait spots, oligopolyposis, glioblastoma and lymphoma. A 24-year-old male, under surveillance for CMMRD, developed Crohn's ileitis after total colectomy with end ileostomy for colorectal cancer and failed to respond to oral corticosteroids. The patient underwent induction and maintenance of remission with vedolizumab infusions. We report the first patient with CMMRD developing Crohn's disease...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/28453769/preoperative-vedolizumab-and-postoperative-outcomes-in-inflammatory-bowel-disease-does-smoke-always-mean-fire
#14
Paulo Gustavo Kotze, Takayuki Yamamoto
No abstract text is available yet for this article.
May 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28453764/response-to-preoperative-vedolizumab-and-postoperative-outcomes-in-inflammatory-bowel-disease-does-smoke-always-mean-fire
#15
Amy L Lightner, Edward V Loftus
No abstract text is available yet for this article.
May 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28449273/systematic-review-the-safety-of-vedolizumab-for-the-treatment-of-inflammatory-bowel-disease
#16
REVIEW
W A Bye, V Jairath, S P L Travis
BACKGROUND: Vedolizumab specifically recognises the α4β7 integrin and selectively blocks gut lymphocyte trafficking: potentially, it offers gut-specific immunosuppression. AIM: To review the safety of vedolizumab and summarise post-marketing data to assess if any safety concerns that differ from registration trials have emerged. METHOD: A systematic bibliographic search identified six registration trials and nine cohort studies. RESULTS: Integrated data from registration trials included 2830 vedolizumab-exposed patients (4811 person-years exposure [PYs]) and 513 placebo patients...
July 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28434387/cost-utility-of-biological-treatment-sequences-for-luminal-crohn-s-disease-in-europe
#17
Fanni Rencz, László Gulácsi, Márta Péntek, Krisztina B Gecse, Axel Dignass, Jonas Halfvarson, Fernando Gomollón, Petra Baji, Laurent Peyrin-Biroulet, Peter L Lakatos, Valentin Brodszky
BACKGROUND: This study aims to compare the cost-effectiveness of treatment sequences with available biologics, including adalimumab (ADA), biosimilar infliximab (bsIFX), originator infliximab (IFX) and vedolizumab (VEDO) for luminal Crohn's disease in nine European countries. METHODS: A Markov-model was constructed to simulate five-year medical costs and quality-adjusted life years (QALYs). Data on clinical efficacy were obtained from randomised controlled trials...
April 28, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28424557/vedolizumab-toward-a-personalized-therapy-paradigm-for-people-with-ulcerative-colitis
#18
REVIEW
Robin J Dart, Mark A Samaan, Nick Powell, Peter M Irving
Ulcerative colitis (UC) is a chronic relapsing and remitting inflammatory bowel disease, with a characteristic leukocytic infiltration of the mucosa. Immunosuppression including anti-TNF-α therapy is a mainstay of treatment for many; however, systemic immunosuppression is not universally effective and is associated with potential side effects. The gut-tropic integrin α4β7, which is expressed on leukocytes, mediates migration from the circulation to the intestinal mucosa. Vedolizumab is a monoclonal antibody which blocks the egress of leukocytes via α4β7, preventing accumulation in the mucosa, and attenuating inflammation without systemic immunosuppression...
2017: Clinical and Experimental Gastroenterology
https://www.readbyqxmd.com/read/28407755/inflammatory-bowel-disease-ibd-pharmacotherapy-and-the-risk-of-serious-infection-a-systematic-review-and-network-meta-analysis
#19
Chelle L Wheat, Cynthia W Ko, Kindra Clark-Snustad, David Grembowski, Timothy A Thornton, Beth Devine
BACKGROUND: The magnitude of risk of serious infections due to available medical therapies of inflammatory bowel disease (IBD) remains controversial. We conducted a systematic review and network meta-analysis of the existing IBD literature to estimate the risk of serious infection in adult IBD patients associated with available medical therapies. METHODS: Studies were identified by a literature search of PubMed, Cochrane Library, Medline, Web of Science, Scopus, EMBASE, and ProQuest Dissertations and Theses...
April 14, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28370049/editorial-vedolizumab-in-pregnancy-is-gut-selectivity-as-good-for-baby-as-it-is-for-mum
#20
EDITORIAL
H H Shim, C H Seow
No abstract text is available yet for this article.
May 2017: Alimentary Pharmacology & Therapeutics
keyword
keyword
1883
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"